Full text is available at the source.
Abstract
Obesity is a key driver of metabolic dysfunction-associated steatotic liver disease (MASLD).
- Lifestyle therapy, combined with semaglutide, may improve non-invasive markers of liver fat and fibrosis.
- Bariatric surgery could offer additional benefits for liver health compared to lifestyle modifications alone.
- The effects of these interventions on hepatic conditions were assessed through non-invasive methods.
Simplified